Abstract. The antithrombin-Ill-independent effect of heparin was studied in the following thrombin-catalyzed reactions: activation of purified plasma factor V and partially purified plasma factor VIII:C, generation of factor Vu from the platelets and, in the presence of collagen, of the platelet procoagulant activity. Five heparin fraclions and a heparinoid were compared to crude heparin. Crude heparin was a more potent inhibitor of these reactions than the fractions or the heparinoid. The inhibitory action of heparin (fractions) appeared to be the result of the formation of a complex between heparin and thrombin that alters the specihcity of thrombin towards high molecular weight substrates. The inhibition of these thrombindependent feedback reactions in blood coagulation might be of importance in the mechanisms for the dissociation between the antithrombotic and hemorrhagic properties of low molecular weight heparins.
Introduction
Heparin is one of the most important drugs for the treatment and prevention of venous thrombosis and thromboembolism. However, it still presents many puzzling questions on diflerent levels to clinicians and clinical chemists, biologists, biochemists and certainly not least for the pharmaceutical industry. Clinicians and clinical chemists know that the major drawback to the therapeutical use of heparin is the absence of any reliable laboratory test to keep the patient in the narrow range that ensures an efficient antithrombotic action but will not cause a hemorrhagic tendency. From the literature it is evident that the properties ofheparin to catalyze factor X" and/or thrombin inactivation by antithrombin III do not suffrciently reflect the complexity of in vivo heparin actions. Research over the last few years has led to the development of heparin fractions of known compositions which allowed considerable progress in understanding the structure-function relationships. Our contribution, as biochemists of blood coagulation, is to identify the complete spectrum of heparin-sensitive reactions, to develop a relevant in vitro de-termination of the action of heparin and to establish their correlation with in vivo effects.
As thrombin formation is the central process in hemostasis and thrombosis, the inhibition by heparin of thrombin formation has been our main focus of interest. It should be appreciated that heparin can inhibit thrombin by 2 separate mechanisms, i.e. the antithrombin activity can be either antithrombin-Ill-dependent or -independent.
Thrombin Generation and Feedback Mechanisms The mechanisms leading to thrombin formation are, on the one hand, a series of proenzyme activation reactions (factor VII -> factor X -+ factor II) and on the other hand interactions at a phospholipid-solute interphase []. Procoagulant, negatively charged phospholipids are provided by the membrane of activated platelets and wounded cells [2] . The assembly of an enzymatic complex at the phospholipid surface is completed by the presence of non-enzymatic protein cofactors (respectively tissue factor, factor VIII. and factor V") [3] [4] [5] . The interaction of thrombin and platelets is a complicated process. Thrombin once formed in trace amounts governs a set of positive feedback reactions. Thrombin is a potent platelet activator and induces the release reactions by which factor V becomes available. Platelet factor V seems to contribute more to thrombin generation and hence to hemostasis and coagulation than plasma factor V does. This was demonstrated within a group of factor-V-deficient patients, where the severity of bleeding was shown to depend on the platelet rather than on the plasma factor V deficiency [6] . Thrombin also converts factor V and factor VIII into their activated forms. Together with collagen, thrombin generates the appearance of a procoagulant surface at the outer membrane of the platelets [2] . If the thrombin formation were not controlled by natural inhibitors and regulatory processes (such as inactivation of factors Vu and VIII. by activated protein C), these coagulation factors and platelet interactions would result in an explosive thrombin formation.
The Antithrombin-I I I -Dependent Action of Heparin The main anticoagulant function of heparin is to enhance the inactivation ofthe serine proteases of blood coagulation (thrombin, factor X", IXu, XI" and XII) by antithrombin III (AT IID. Three models are currently described. (a) Heparin binds to AT III, inducing a conformational change [7, 8] ; (b) the reactivity of thrombin with AT III is enhanced by the binding of heparin to thrombin [9, l0] ; and (c) a ternary complex is formed and stabilized by the interaction of AT III and thrombin with heparin, the socalled template model I l-13]. These models are no1 mutually exclusive.
Factor X" inactivation by the heparin-AT III complex is accounted for by the interaction of factor X" with AT III and not by the interaction of factor Xu with heparin bound to AT III. Factor XII" is inhibited in the same way. The saccharide structure required to potentiate the inactivation of factor X" and factor XII" is contained within the ATIll-binding region [4] . Heparin fractions with a molecular weight higher than 3,400 are equally active [5] . On the contrary, thrombin and factors IXu and XIu can bind to the heparin molecule as well as to the AT III molecule. The potency of heparin in caralyz' ing the AT III thrombin reaction increases with the molecular weight of heparin [l6] . At high concentrations, heparin has an additional effect by catalyzing the inhibition of thrombin by heparin cofactor II [7] .
However, because thrombin formation is a phospholipid-bound process, the inactivation ofthe serine proteases ofblood coagulation has to be considered as it occurs at the phospholipid-solute interphase, where the enzyme is located when it is physiologically active, rather than on the free enzyme. It has already been known for several years [18, l9] that factor X" bound to phospholipids is much less accessible to the inactivation by AT Ill-heparin than free factor Xu is. This was recently demonstrated to be also the case when factor X" and factor Vu bind to activated platelets, therefore requiring that these complexes are cleared from blood before the heparin therapy can be eflective 120,211.
T he A nt it hr o mbi n-I I I -I ndep e nde nt Effe ct of Heparin Evidence for an AT-Ill-independent eflect of heparin in reactions of blood coagulation and hemostasis is three-fold.
(l) Some heparin fractions with a low affrnity for AT III, which are virtually devoid of any antithrombin or antifactor X" activity in vitro significantly increased hemorrhage without influencing the in vivo antithrombotic effect in animal experimental models [22] . Furthermore this low affrnity heparin fraction potentiated the antithrombotic action of a high affrnity heparin oligosaccharide of a molecular weight lower than 3,500 which only had an antifactor Xu activity in vitro [23] .
(2)In a system consisting ofpurified coagulation factors and synthetic phospholipids, heparin can inhibit prothrombin and factor X activation. This effect was attributed to the deplacement of the bound proteins from the phospholipid surface 124-261. However, these experimental results can alternatively be explained by an effect of heparin on the thrombin-catalyzed factor VIII activation. As the effect of heparin in these experiments was practically abolished if the activated factor VIII was present, the latter explanation seems more probable. Also the fact that in an AT-Ill-depleted plasma the effect of heparin on the inhibition of factor Xu or thrombin generatioir is almost negligible, supports this notion [27] . Comparison of crude heparin and low affrnity heparin in prothrombin activation in AT-Ill-depleted plasma showed that the inhibitory effect of both heparins was similar. These experiments do not exclude an eflect due to other serine protease inhibitors. No further insight was brought in the mechanism underlying the deplacing effect by heparin of protein-lipid interactions [28] .
(3) Conflicting data have been reported showing that heparin either induced [29] or inhibited platelet aggregation [30] . It was shown that some of the heparin effects were related to an interaction with platelet functions [31] . Bleeding caused by heparin has been attributed to a direct effect on platelets. The original observation of Salzman et al. [32] that high molecular weight, low AT III affinity heparin fractions, were more reactive on platelets than low molecular weight, high AT III affinity fractions, suggested a correlation between the hemorrhagic eflect of heparin and the anticoagulant properties in vitro. However, this correlation is far from being a strong one [33] .
In this study, we show that an AT-IIIindependent effect ofheparin in blood coagulation and platelet reactions might be the result of an interaction between thrombin and heparin. To this end, we used purified proteins, synthetic phospholipids or washed platelets under well defined kinetic condi-tions, together with different heparin fractions of known antithrombotic/hemorrhasic properties 134-311.
Materials and Methods
Experimental procedures for protein and phospholipid preparation as well as platelet isolation are as described earlier [38] . Purification of bovine factor VIII:C was performed by diflerential precipitation by polyethylene glycol. The determination of the platelet factor Vu generation upon the addition of thrombin, and of the platelet procoagulant activity in the presence ofthrombin and collagen, has been reported previously [38] .
Heparin Fractions
We were interested in measuring the effect of heparin fractions that had already been used in clinical trials and in vivo animal experimental models [34-371. They were supplied by the following laboratories: Choay Institute (CY 216, an ethanol precipitation fragment; CY 222, a fragment obtained by nitrous acid depolymerization), Pharmuka Laboratories (FF 32038, a crude heparin; PK 10169. obtained by controlled depolymerization; EMT 966, EMT 967, obtained by gel filtration of PK 10169) and Organon Laboratories (crude heparin and Org 10172, a sulphated mucopolysaccharide). The average molecular weights, antifactor X, and antithrombin activities are listed in table I.
PuriJied Plasma Factor V Activation Bovine factor V (100 nM) was incubated for 5 min at 37 " C in the presence of 3 mM CaCl2. The reaction was started by the addition of thrombin (usually 0.3 nM). Aliquots were taken in time, diluted l:1,000 in buffer containing 50 mM Tris, 175 mM NaCl, 5 mM CaCl2 and 0.5 mg/ml HSA, pH 7.9. Factor Vu activity was measured as previously described [38] .
Partially Purified Factor VIII:C Activation Partially purified factor VIII:C was activated by bovine thrombin in the following way: factor VIII:C (20 1tl, 27 U/ml) was incubated in I ml Michaelis buffer containing29 mM sodium barbiturate,29 mM sodium acetate and I l6 mMNaCl, pH 7.3. The reaction was started with the addition of thrombin (3 nM). Aliquots (10 pl) of a factor-Vlllu-containing sample were added to the clotting assay containing 60 pl factor-Vlll-defrcient plasma, 4 nM factor IX", 50 F,l./ phospholipid [(250lo phosphatidylserine (PS), 75olo phosphatidylcholine (PC)l and l0 mM CaCll The clotting time was recorded on an automatic coagulometer. A calibration curve was established with normal pool plasma activated with 9 nM thrombin in order to determine the amount of factor VIII' present in the sample.
Inhibilion Studies
The assessment of a heparin effect on thrombincatalyzed reactions can be made provided that the following conditions are met.
(l) Thrombin formation by the prothrombinase complex can be measured as a function of varying concentrations of an accessory component (factor Vu or phospholipids) under the conditions where the accessory component under investigation is the only ratelimiting factor of the reaction. Factor VIIIa can be determined in a clotting assay in a cornparable manner.
(2) An effect of heparin on a thrombin-catalyzed reaction can be assessed if the manner in which this reaction depends on the thrombin concentration is known. This is shown, in frgure l, for the thrombincatalyzed factor VIII activation and in figure 2 for the thrombin-catalyzed factor V activation. Throughout this study, excess thrombin concentrations were avoided in order to be able to quantitate the heparin thrombin (nM)
effects. We previously showed that a similar relationship exists in the thrombin-catalyzed platelet V" generation and thrombin-plus collagen-induced platelet procoagulant activity [38] . (3) The interaction between heparin and thrombin results in the formation of a l:l complex. This complex formation leaves unaflected the catalytic site of thrombin towards the synthetic chromogenic substrate, but has an altered enzymatic activity towards macromolecular substrates. In contrast with others [39] , we found that heparin and heparin lractions up to 200 pg/ml had no effect on the catalytic efficiency of' thrombin on the chromogenic substrate 52338 when the substrate concentration is above or near the K. (data not shown).
Upon the formation of a heparin-thrombin complex, the inhibition of the thrombin activity on its macromolecular substrate results in a decrease in the rate of the thrombin-catalyzed reaction. The IC5s is the heparin concentration required to obtain halfmaximal reaction velocity. The IC56 values can be 
Results and Discussion

Demonstration of the Absence of Interaction of Heparin with Other
Components than Thrombin Before we could attribute to heparin the observed effects on the thrombin-catalyzed reactions, we had to exclude any effect of heparin carried over into the assay mixtures. Therefore, as an effect ofheparin on the protein-phospholipid interaction has been reported [22] , we had to estimate the effect of 0.1 Fig. 1 . Dependency of the lactor VIII activation on thrombin concentralion. Normal plasma is incubated at 37'C with varying bovine thrombin concentrations for l5 s. A sample is brought to the lactor X acrivation mixture containing phospholipids vesicles (250/o PS/75ok PC, 5X l0-5 M), CaCl2 (l0mM) and facror IXu (4.0x l0-e M).The rate of lactor X activation is measured after 2 and 4 min. The results are expressed as rate of the factor Xu lormation per minute per unit factor vlllu present in I ml plasma. Fig. 2 . Dependency of factor V activation on thrombin concentration. Purified bovine factor V 000 nM) was incubated for 5 min at 37 'C in a buffer containing 50 mM Tris, 175 mM NaCl, 3 mM CaCl2, 0.5 mg human serum albumin/ml in the presence of varying thrombin concentrations. Factor Vu activity was delermined as described in 'Materials and Methods'.
. heparin on separate protein-lipid interactions. This was done by use of a protein-lipid equilibrium technique according to van de Waart et al. [40] . Factor X" (0.1 1tM), factor V" (0.1 ytM) or prothrombin (0.05 pM) were incubated with large volume phospholipid vesicles, 25 pM (200/o PS -80o/o PC), in 50 mM Tris, 100 mM NaCl, pH 7.5, at 20"C. After centrifugation for 30 min at 30,000 g at 20"C, the concentrations of the bound proteins were estimated by determination of the remaining activity in the supernatant (factor Xu was determined on 52337, factor V" by the factor Vu assay and prothrombin after activation by Echis carinatus venom coagulant). Both heparin FF 32038 and PK 10169 at a final concentration of 0.5 mglml could not displace factor Vu, factor Xu or prothrombin from the phospholipid surface. The concentrations ofbound protein in the presence and absence ofheparin (fraction) were: 0.02 W,0.10 pM, 0.03 pM for factor Xu, factor V" and prothrombin, respectively.
The effect of heparin on the thrombin-catalyzed factor VIII activation is measured in a clotting assay using a factor-Vlll-deficient plasma; therefore heparin is carried over and indeed influences the clotting times. This problem is circumvented by making a calibration curve for the factor VIII. formation in the presence of the same amounts of heparin as those that are carried over. In that way, heparin does not affect the relative changes occurring during the thrombin -catalyzed factor VIII activation. In all other studies, we used a completely purihed system, in which no effect of heparin carried over into the assay was observed. This was demonstrated by letting the substrate of thrombin be fully activated in the absence ofheparin and adding a high heparin concentration immediately before transferring a sample to the measuring system. No effect of heparin or heparin fractions at final concentrations of up to 0.5 mglml was observed after a l0-min incubation, showing that the amount of thrombin-activated substrate was independent ofthe presence ofheparin in the activation mixture. This demonstrates that heparin did not interfere with the assembly or the functioning of the prothrombinase complex.
In the reactions where platelets are involved, we had to rule out the presence of AT III in the washed platelet preparations [41] . This was done by incubation ofwashed platelet suspension (107/ml) with 5 nM thrombin in the presence of heparin (fractions) (10 pglml).After 20 min, the amidolytic activity of thrombin appeared to be unaffected. In order to discriminate between an effect of heparin on the thrombin-induced factor Vu generation and an eflect related to the binding of heparin to platelets, we measured the eflect of heparin on the beta-thromboglobulin release, induced by either thrombin or collagen. Only the thrombin-induced release of beta-thromboglobulin was aflected by heparin (900/o inhibition of the release reaction at 50 pg heparin/ml), showing that the reaction was occurring between thrombin and heparin and was not due to an efTect of heparin on platelets.
Effect of Heparin (Fractions) on the Thrombin-Catalyzed Plasma Factor VIII Activation We used a semi-quantitative estimation of the effect of heparin on the thrombin-catalyzed factor VIII activation. Figure 3 shows the time course of the factor VIII activation in the absence and presence of varying amounts of unfractionated heparin (FF 32038). Heparin has an effect both on the initial rate of the factor VIII activation and on Antithrombin-III-lndeoendent Effect of Heoarin Fig.3 . Effect of crude heparin FF 32038 on the thrombin-catalyzed lactor VIII activation. Isolated factor VIII:C was incubated with thrombin (3 nM\ and varying concentrations of heparin FF 32038. o = No heparin; o = 0.14 pglml; r = 0.70 pglml; a = 1.43 pglml; I = 2.9 pg/ ml n = 5.'7 pg/ ml. At timed intervals, factor Vlllu-containing samples were transferred to the assay. Factor VIII, was determined by using a calibration curve established with normal plasma as described in 'Materials and Methods'. the rate of inactivation of factor VIII.. It was observed that the level offactor VIIIa after 4 min was in all cases lower in the absence than in the presence of heparin. This stabilizing effect of heparin could be due to an effect either on thrombin, and/or on the factor VIII,. Further experiments are required for a better understanding. We estimated the effect on the initial rate of activation, of heparin FF 32038, PK 10169 and Org 10172 (fig.4) . The IC5e values were found to be 0.5 pg/ml,1.75 pglml and 25 14/ml, respectively.
Effect of Heparin (Fractions) on the Thrombin-Catalyzed P lasma Factor V Activation Bovine factor V (100 nM) was incubated at 3l "C with calcium (3 mM) and varying concentrations of heparin (fractions). The reaction was initiated by the addition of thrombin (0.3 nM). After 6 min, 1:1,000 diluted samples were assayed for the factor Vu activity. The percentage of the residual factor V" concentration was plotted as a function of the heparin concentration (hg. Effect of Heparin Fractions on the Thrombin-Induced Platelet Factor Vo Generation and on the Thrombin-plus Collagen-I nduced Platelet Procoagulant Activity We have previously described a direct inhibitory eflect of heparin on thrombin in platelet activation [38] . We tested the effect of heparin on the thrombin-induced platelet factor Vu generation and on the thrombinplus collagen-induced platelet procoagulant activity. We have extended the previous study to the effect ofother heparin fractions, PK 10169 and 2 fractions obtained by gel filtration of PK 10169: EMT 966 and EMT 961 . The results of these studies are depicted heparin, pglml in table II. Whereas in the platelet factor Vu generation the IC5s values are very similar (+ 20 pe/ml), there are striking differences for the procoagulant activity of thrombinplus collagen-activated platelets. Heparin FF 32038 inhibited the thrombin-plus collageninduced procoagulant activity with an IC5s of 2 pg/ml, whereas much higher concentrations of PK 10169 and EMT 967 would be required to obtain the same extent of inhibition.
Conclusions
From in vitro studies we have been able to demonstrate a direct inhibitory effect of heparin on several thrombin-dependent reactions in blood coagulation. An AT-III-independent effect of heparin is shown on the thrombin-calalyzed factor VIII activation. Table Il . Effect of heparin on the thrombin-induced platelet factor Vu generation and on the thrombinplus collagen-induced platelet procoagulant activity Compound IC:o 0tg/ml) factor Vu procoagulant generation activity sity of heparin is independent of the a{Iinity for AT III, but correlates with the thrombinbinding 1421, and a recent report describes that the surface charge as well as the surface charge density of heparin [43] is important in thrombin-binding.
Sulphatation seems to be an important parameter for the nonspecifrc binding of polysaccharides to various proteins. This not only holds for the heparin-protease interaction, but also for the inhibiting action of pentosane polysulphate [44] , recently shown to be caused by inhibition of the thrombininduced factor VIII:C activation lWagenvoord, unpublished resultsl. Also the interaction of heparin fractions with endothelium is seen to be strongly dependent upon the degree of sulphatation fBarzu, personal communication]. Further studies are required to better characterize the in vivo signihcance of this effect, as to the dissociation between antithrombotic and hemorrhagic effect of low molecular weight heparin fractions. Inhibition by heparins ofthe feedback activation reactions of thrombin by a process independent of AT III anyhow seems to be one of the mechanisms by which heparins modulate the thrombin formation and hence hemostasis and thrombosis. Human washed platelets (4.6X 106/ml) were incubated for 3 min at 37 "C with 3 mMcalcium and varying concentrations of heparin (fractions). The reaction was started with the addition of the activator (thrombin 0.5 nM or thrombin 0.3 nM plus collagen 5 pglml) and after 5 min the respective activities were determined. This is in agreement with the results of Ofosu et al.126l obtained by a completely different method.
In purihed systems, the same effect was shown on the plasma factor V activation and, as demonstrated earlier [38] , on the platelet factor Vu generation and platelet procoagulant activity. We have demonstrated that this effect was due to a nonspecific heparinthrombin interaction. We have not been able to confirm the observation of Walker and Esmon [24] that the AT-Ill-independent effect of heparin is due to interference with the protein-lipid interaction, as we performed binding experiments that allow direct determination of the protein bound to phospholipids and were unable to find any effect of heparin on this binding.
Structural characteristics of the heparin molecule have been described that are required for protease-binding: the charge den-
